30 Nov 2017 Jahr - FDA approved Sublocade, the first once-monthly
injectable buprenorphine product for the
treatment of moderate-to-severe opioid use
disorder in adult patients who have initiated
treatment with a transmucosal (absorbed
through mucus membrane) buprenorphine-
containing product. It is indicated for patients
that have been on a stable dose of
buprenorphine treatment for a minimum of
seven days.
Zugefügt zum Band der Zeit:
Opioids and the FDA
Datum:
